Ionis Pharmaceuticals Inc Ionis (NASDAQ: IONS) Announces Roche to Assess Tominersen for HD in New Phase II Trial Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) disclosed that its associate, Roche, has decided to start a new Phase II study to assess Tominersen in Huntington's disease (HD). After stopping dosing in
Ionis Pharmaceuticals Inc Ionis (NASDAQ: IONS) and AstraZeneca Strike Deal to Develop and Commercialize Eplontersen Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and AstraZeneca Plc (NASDAQ: AZN) both have inked an agreement to create and market Eplontersen. Eplontersen is a new antisense medicine of IONS for the